ONX 0912: Clinical Trials

5 terminated, 2 completed, 1 withdrawn. 8 Phase 1, 5 Phase 2.

By phase and status

Phase	Trials	Status
Phase 1	8	Terminated 5, Completed 2, Withdrawn 1
Phase 2	5	Terminated 3, Completed 1, Withdrawn 1

Follow ONX 0912: new trials by email Literature Review of ONX 0912 trials Research Report on ONX 0912

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Phase 1b/2 Study of Oprozomib in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma Oprozomib, Sorafenib - Advanced Hepatocellular Carcinoma	Phase 1 / Phase 2	Withdrawn	Amgen		2014-12-01	2017-05-02
A Phase 1 Study of Oprozomib to Assess Food Effect, Drug-Drug Interaction With Midazolam, and Safety and Tolerability in Patients With Advanced Malignancies Oprozomib, Midazolam - Advanced Non-Central Nervous System (CNS) Malignancies	Phase 1	Terminated	Amgen	43	2014-08-01	2021-02-21
A Study of Oprozomib, Pomalidomide, and Dexamethasone in Adults With Primary Refractory or Relapsed and Refractory Multiple Myeloma Oprozomib, Pomalidomide, Dexamethasone - Multiple Myeloma	Phase 1	Terminated	Amgen	33	2014-07-30	2021-04-27
A Study of Oprozomib, Melphalan, and Prednisone in Transplant Ineligible Patients With Newly Diagnosed Multiple Myeloma Oprozomib, Melphalan, Prednisone - Multiple Myeloma	Phase 1 / Phase 2	Completed	Amgen	9	2014-01-01	2017-05-02
Oprozomib and Dexamethasone,in Combination With Lenalidomide or Oral Cyclophosphamide to Treat Newly Diagnosed Multiple Myeloma Oprozomib, Lenalidomide, Dexamethasone - Multiple Myeloma	Phase 1 / Phase 2	Terminated	Amgen	22	2013-10-28	2022-11-14
Phase 1b/2, Multicenter, Open-label Study of Oprozomib and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma Oprozomib, Dexamethasone - Multiple Myeloma	Phase 1 / Phase 2	Terminated	Amgen	65	2013-07-02	2020-07-13
Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic Malignancies oprozomib - Multiple Myeloma, Waldenstrom Macroglobulinemia	Phase 1 / Phase 2	Terminated	Amgen	210	2011-10-15	2022-11-08
Phase 1 Study of Oprozomib Administered Orally in Patients With Advanced Refractory or Recurrent Solid Tumors Oprozomib - Solid Tumors	Phase 1	Completed	Amgen	44	2010-04-01	2017-05-02

Conditions studied

Multiple Myeloma (5)  ·  Neoplasms (1)  ·  Waldenstrom Macroglobulinemia (1)

Sponsors

Amgen (8)

Countries

United States (7)  ·  France (1)  ·  Greece (1)  ·  Italy (1)  ·  Netherlands (1)

Results publications

PMID 31229804

NIH funding

2014 (1)